VBIO (Valion Bio, Inc. Common Stock) Stock Analysis - News
Valion Bio, Inc. Common Stock (VBIO) is a publicly traded the market company. As of May 21, 2026, VBIO trades at $0.85 with a market cap of $2.70M and a P/E ratio of 0.00. VBIO moved +0.00% today. Year to date, VBIO is +0.00%; over the trailing twelve months it is flat. Its 52-week range spans $0.80 to $1.21. Rallies surfaces VBIO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
What changed in VBIO news today?
Valion Bio Q1 Operating Expenses Climb to $5.6 M; Entolimod Scale-Up Advances: Valion Bio’s first quarter as a clinical-stage immunotherapeutics company saw operating expenses rise to $5.6 M from $1.4 M, a net loss of $6.2 M ($2.23/share), and cash reserves of $7.2 M at March 31. The company advanced its Entolimod platform with FDA Animal Rule support, Fast Track and Orphan Drug designations, a 200-fold scale-up yielding ~1.3 million doses, and deeper engagement with BARDA, NIAID and other agencies while integrating its Velocity Bioworks CDMO.
LoConti Joseph E. bought 1.00K (~$200) on Jul 29, 2021.
LoConti Joseph E. bought 13.00K (~$2.60K) on Jul 20, 2021.
LoConti Joseph E. bought 40.00K (~$6.40K) on Jul 19, 2021.
VBIO Analyst Consensus
VBIO analyst coverage data. Average price target: $0.00.
Common questions about VBIO
What changed in VBIO news today?
Valion Bio Q1 Operating Expenses Climb to $5.6 M; Entolimod Scale-Up Advances: Valion Bio’s first quarter as a clinical-stage immunotherapeutics company saw operating expenses rise to $5.6 M from $1.4 M, a net loss of $6.2 M ($2.23/share), and cash reserves of $7.2 M at March 31. The company advanced its Entolimod platform with FDA Animal Rule support, Fast Track and Orphan Drug designations, a 200-fold scale-up yielding ~1.3 million doses, and deeper engagement with BARDA, NIAID and other agencies while integrating its Velocity Bioworks CDMO.
Does Rallies summarize VBIO news?
Yes. Rallies summarizes VBIO news with ticker-specific context, catalysts, source links, and AI-generated market summaries when news is available.
Is VBIO research on Rallies investment advice?
No. Rallies provides research, data, and educational context for VBIO. It does not provide personalized investment advice.
